Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
Northwestern University
Northwestern University
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)
Asan Medical Center
M.D. Anderson Cancer Center
Northwestern University
UNC Lineberger Comprehensive Cancer Center